UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer
Enrolling By Invitation
99 years or below
All
Phase
2
32 participants needed
1 Location
Brief description of study
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: pancreatic cancer
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 833642
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
